Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 4Oligodendroglioma 2Astrocytoma 2Recurrence 1Pathologic Processes 1Neuroectodermal Tumors 1Neoplasms, Neuroepithelial 1Neoplasms, Nerve Tissue 1Neoplasms, Glandular and Epithelial 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Histologic Type 1Neoplasms 1Healthy Adult Participants 1Disease Attributes 1

Interventions

Oncolytic Virotherapy 2vorasidenib 1repotrectinib 1pralsetinib 1pembrolizumab 1pamiparib 1interferon gamma-1b 1Vorinostat 1Radiation 1ONC206 1Interferon-gamma 1Immunotherapy 1Antibodies, Monoclonal 1Afatinib 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neuroectodermal Tumors × vorasidenib × Clear all
NCT05592743 2024-11-05

Vorasidenib Expanded Access Program

Servier

Approved for marketing
CNS

Astrocytoma, Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Oligodendroglioma, Pathologic Processes, Recurrence, Neuroectodermal Tumors, Neoplasms, Neuroepithelial, Disease Attributes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡